Novel strategies for systemic treatment of endometrial cancer

Bibliography

• MCLAUGHLIN JR, FIELDS ALA, MAO Y et al: CanadianCancer Statistics 1999. Natl. Cancer Inst. Can. Toronto, Ontario, Canada (1999):34.
   Google Scholar
• CREASMAN WT, ODICINO F, MAISONNEUVE P et al:Carcinoma of the corpus uteri. J Epidemiol. BiostaL (1998) 3(0:35–61.
   Google Scholar
• MOORE TD, PHILLIPS PH, NERENSTONE SR, CHESON BD: Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions.' Clin. Oncol. (1991) 9(6):1071–1088.
   Google Scholar
• ••Review article.
   Google Scholar
• ROBERTS JA, BRUNETTO VL, KEYS HM et al.: A Phase 3 randomized study of surgery versus surgery plus adjunctive therapy in intermediate risk endometrial adenocarcinoma (GOG 99). Society of Gynecologic Oncologists, 99th Annual Meeting (1998):70.
   Google Scholar
• •New philosophy in care of women with stage 1 intermediate risk uterine cancer.
   Google Scholar
• PIVER MS, BARLOW JJ, LURAIN JR, BLUMENSON LE:Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer (1980) 45:268–272.
   Google Scholar
• PODRATZ KC, O'BRIEN PC, MALKASIAN GDJ: Effects ofprogestational agents in treatment of endometrial carcinoma. ObsteL Gynecol. (1985) 66:106–110.
   PubMedGoogle Scholar
• GREVEN KM, CORN BW: Endometrial cancer. Curr. Pro& Cancer (1997) March/April:113–127.
   Google Scholar
• KAUPPILA A, JANNE 0, WIEAND HS: Treatment of advanced endometrial adenocarcinoma with a combined cytotoxic therapy. Predictive value of cytosol estrogen and progestin receptor levels. Cancer (1980) 46:2162–2167.
   Google Scholar
• BARAKAT RR, PARK RC, GRIGSBY PW et al.: Corpus: epithelial tumors. In: Principles and Practice of Gyneco-logic Oncology (2nd Edition). Hoskins WJ, Perez CA, Young RC (Eds.), Lippicott-Raven, Philadelphia, USA (1997):859–896.
   Google Scholar
• •Review of uterine cancer.
   Google Scholar
• THIGPEN JT, HOMESLEY HD: A randomized study of medroxyprogesterone acetate (MPA) 200 mg versus 1000mg in the treatment of advanced or recurrent carcinoma of the endometrium. Proc. ASCO (1991).
   Google Scholar
• SALL S, DISAIA P, MORROW CP: A comparison of medroxyprogesterone serum concentrations by oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma. Am. J. ObsteL Gynecol. (1979) 135:647–650.
   PubMed Web of Science ®Google Scholar
• KAUPPILA A: Progestin therapy of endometrial, breast and ovarian carcinoma. Acta Obstet. Gynecol Scand. (1984) 63:441–450.
   PubMed Web of Science ®Google Scholar
• LENTZ SS, BRADY MF, MAJOR F, REID GC, SOPER JT: High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. (1996) 1 4 (2):357–361.
   Google Scholar
• MARTIN-HIRSCH PL, JARVIS G, KITCHENER H et al.: Pro gestagens for endometrial cancer. [computer program]. Update Software Ltd; Middle Way, Oxford (2000), The Cochrane Library. Keywords: Endometrial cancer; cancer In File.
   Google Scholar
• •Pivotal paper on adjuvant hormone therapy for stage 1 endometrial cancer.
   Google Scholar
• PUSTILNIK T, BURKE TVV: Adjuvant chemotherapy for high-risk endometrial cancer. Semin. RadiaL Oncol (2000) 10(0:23–28.
   PubMedGoogle Scholar
• HORTON J, BEGG CB, ARSENEAULT J: Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat. Rep. (1978) 62:159–161.
   PubMedGoogle Scholar
• PAWINSKI A, TUMOLO S, HOESEL G et al.: Cyclophos-phamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a random-ized Phase II study of the EORTC Gynecological Cancer Cooperative Group. Eur.J. ObsteL Gynecol Reprod. Biol. (1999) 86:179–183.
   PubMed Web of Science ®Google Scholar
• O'BRIEN ME, KILLACKEY M: Adjuvant therapy in high-risk endometrial adenocarcinoma. Proc. ASCO (1994) 13:249.
   Google Scholar
• MORROW CP, BUNDY BN, HOMESLEY HD: Doxorubicinas an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage 1 and occult stage II: A Gynecologic Oncology Group study. Gynecol. Oncol. (1990) 36:166–171.
   PubMed Web of Science ®Google Scholar
• CORNELISON TL, BAKER TR, PIVER S, DRISCOLL BA: Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyproges-tione acetate in the treatment of endometrial carcinoma. Gynecol. Oncol. (1995) 59:243–248.
   PubMed Web of Science ®Google Scholar
• HORTON J, ELSON P, GORDON P: Combination chemotherapy for advanced endometrial cancer: An evaluation of three regimens. Cancer (1982) 49 (Suppl. 2):2441–2445.
   Google Scholar
• COHEN CJ, BRUCKNER HW, DEPPE G: Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. ObsteL Gynecol. (1984) 63:719–726.
   PubMed Web of Science ®Google Scholar
• AYOUB J, AUDET-LAPOINTE P, METHOT Y: Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol. Oncol (1988) 31:327–337.
   PubMed Web of Science ®Google Scholar
• EDMONSON JH, KROOK JE, HILTON JF: Randomized Phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endome-trial carcinoma. Gynecol. Oncol (1987) 28:20–24.
   PubMed Web of Science ®Google Scholar
• KIM YB, HOLSCHNEIDER CH, GHOSH K: Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Cancer (1997) 79:320–327.
   PubMed Web of Science ®Google Scholar
• RANDALL TC, KURMAN RJ: Pr ogestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet. Gynecol. (1997) 90:434–440.
   PubMed Web of Science ®Google Scholar
• CHRISTEN RD, MCCLAY EF, PLAXE SC: Phase I/pharma-cokinetic study of high-dose progesterone and doxorubicin. j Clin. Oncol. (1993) 11:2417–2426.
   PubMed Web of Science ®Google Scholar
• WANG L, YANG C, TRAIL P: Reversal of the multidrug resistance (MDR) phenotype with megestrol acetate. Proc. AACR (1991) 32:337.
   Google Scholar
• SLAVIK M, PETTY WM, BLESSING JA, CREASMAN WT, HOMESLEY HD: Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gyneco-logic Oncology Group study. Cancer Treat. Rep. (1984) 68 (5):809–811.
   PubMedGoogle Scholar
• EDMONSON JH, KROOK JE, HILTON JF: Ineffectivenessof tamoxifen in advanced endometrial carcinoma after failure of progesting treatment. Cancer Treat. Rep. (1986) 70:1019–1020.
   PubMedGoogle Scholar
• BONTE J, IDE P, BILLIET G, WYNANTS P: Tamoxifen as apossible chemotherapeutic agent in endometrial adenocarcinoma. Gynecol Oncol. (1981) 11:140–161.
   PubMed Web of Science ®Google Scholar
• SWENERTON KD: Treatment of advanced endometrialadenocarcinoma with tamoxifen. Cancer Treat. Rep. (1980) 64(6-7):805–811.
   PubMedGoogle Scholar
• KLIJN J, DEN HOED KLINIEK D: Multicentre Phase II study of the selective estrogen receptor modulator (SERM) Ly 353381 in advanced or recurrent endome-trial cancer - objective responses in progestagen sensitive patients. Proc. ASCO (2000):386a.
   Google Scholar
• DE VRIESE G, BONTE J: Possible role of goserelin, an agonist in the treatment of gynecological cancers. Eur. J. Cancer Clin. Oncol (1993) 14:187.
   Google Scholar
• GALLAGHER CJ, OLIVER RT, ORAM DH: Anew treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br. J. Obstet. Gynecol. (1991) 98:2224.
   Google Scholar
• JEYARAJAH AR, GALLAGHER CJ, BLAKE PR: Long-term follow-up of gonadotropin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecol. Oncol. (1996) 63:47–52.
   PubMed Web of Science ®Google Scholar
• COVENS A, THOMAS G, SHAW P: A Phase II study ofleuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol. (1997) 64:126–129.
   PubMed Web of Science ®Google Scholar
• ROSE PG, BRUNETTO V, VANLE L, BELLI WALKER JL, LEERB: A Phase II trial of anastrozole in advanced recurrent or persistent endometrial cancer: a gyneco-logic oncology group study. Gynecol. Oncol (2000) 78 (2):212–216.
   PubMed Web of Science ®Google Scholar
• LORUSSO P, FOSTER BJ, POPLIN E et al: Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clin. Cancer Res. (1995) 1:1487–1493.
   PubMed Web of Science ®Google Scholar
• ALBERTS DS: Future directions in gynecologic cancers. Semin. Oncol (1999) 26(2 Suppl. 7):125–128.
   Google Scholar
• RANDALL ME, SPIRTOS NM, DVORETSKY P: Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (Phase III): Gyneco-logic Oncology Group study No. 122.1 Natl. Cancer Inst. (1995) 19:13–15.
   Google Scholar
• PISANI AL, BARBUTO DA, CHEN D, RAMOS L, LAGASSE LD, KARLAN BY: HER-2/neu, p53 and DNA analysis as prognosticators for survival in endometrial carcinoma. Obstet. Gynecol. (1995) 85:729–734.
   PubMed Web of Science ®Google Scholar
• OZSARAN AA, TURKER S, DIKMEN Y et al.: p53 staining as a prognostic indicator in endometrial carcinoma. Eur. Gynaec. Oncol (1999) 20:156–159.
   PubMed Web of Science ®Google Scholar
• MAXWELL GL, RISINGER JI, GRUMB C, SHAW H, BENTLEY RC, BARRETT JC: Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. (1998) 58:2500–2503.
   PubMed Web of Science ®Google Scholar
• RISINGER JI, UMAR A, BOYD J, BERCHUCK A, KNUKEL TA,BARRETT JC: Mutations of MSH3 in endometrial cancer and evidence for its role in heteroduplex repair. Nature Genet. (1996) 14:102–105.
   PubMed Web of Science ®Google Scholar
• OZAKI K, ENONMOTO T, YOSHINO K, HONGBO S, NAKAMURA T, FUJITA M: Fhit alterations in endome-trial carcinoma and hyperplasia. Int. J. Cancer (2000) 85:306–312.
   PubMed Web of Science ®Google Scholar
• LYNCH HT, CASEY MJ, LYNCH J, WHITE EK, GODWIN AK:Genetics of ovarian carcinoma. Semin. Oncol. (1998) 25:265–280.
   PubMed Web of Science ®Google Scholar
• Principles and Practice of Gynecologic Oncology. (2nd Edition). Parker MF, Sausville EA, BirerMJ, Hoskins WJ, Perez CA, Young RC (Eds.), Lippincott-Raven, Philadelphia, USA (1997) 3:61–86.
   Google Scholar
• CADUFF RF, JOHNSTON CM, FRANK TS: Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am. J. Pathol. (1995) 1 4 6:182–188.
   Google Scholar
• SAFFARI B, JONES LA, EL-NAGGAR A, FELIX JC, GEORGE J,PRESS MF: Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancer: correla-tion with overall survival. Cancer Res. (1995) 5:5693–5698.
   Google Scholar
• NIIKURA H, SANSANO H, KAGA K, SATO S, YAJIMA A: Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium. Hum. Pathol. (1996) 27:282–289.
   PubMed Web of Science ®Google Scholar
• BORST M, BAKER V, DIXON D: On cogene alterations in endometrial carcinoma. Gynecol. Oncol. (1990) 38:364–366.
   PubMed Web of Science ®Google Scholar
• KACINSKI BM, CARTER D, MITTAL K: High level expres-sion of fms roto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarci-nomas. Int..). Radial Oncol. Biol. Phys. (1988) 15:823–829.
   PubMed Web of Science ®Google Scholar
• SALVESEN HB, IVERSEN OE, AKSLEN LA: Independent prognostic importance of microvessel density in endometrial carcinoma. Br. J. Cancer (1998) 77:1140–1144.
   PubMed Web of Science ®Google Scholar
• CHARNOCK-JONES DS, SHARKEY A, RAJPUT-WILLIAMS J,BURCH D, SCHOGIELD JP, FOUNTAIN SA: Identification and localization of alternately spiced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol. Reprod. (1993) 48:1120–1128.
   PubMed Web of Science ®Google Scholar
• DOLDI N, BASSAN M, GULISANO M, BROCCOLI V, BONCINELLI E, FERRARI A: Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer. Gynecol. Endocrinol. (1996) 10:375–382.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA Y, SATO S, FUTAGAMI M, FUKUSHI Y, SAKAMOTO T, UMENMOTO M: Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol. Oncol. (2000) 77:413–418.
   PubMed Web of Science ®Google Scholar
• LESSEY BA, ALBELDA S, BUCK CA: Distribution of integrin cell adhesion molecules in endometrial cancer. Am. J Pathol. (1995) 1 4 6:717–726.
   Google Scholar
• FUJITA N, YAEGASHI N, IDE Y: Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res. (1994) 54:3922–3928.
   PubMed Web of Science ®Google Scholar
• DE CLERCK YA, SHIMADE H, TAYLOR SM: Matrix metalloproteinases and their inhibitors in tumor progression. Ann. NY Acad. Sci. (1994) 732:222–232.
   PubMed Web of Science ®Google Scholar
• BROWN PD, GIAVAZZI R: Matrix metalloproteinaseinhibition: a review of anti-tumor activity. Ann. Oncol. (1995) 6:967–974.
   PubMed Web of Science ®Google Scholar
• UENO H, YAMASHITA K, AZUMANO I, INOUE M, OKADA Y: Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endome-trial carcinomas. Int. J Cancer (1999) 84:470–477.
   PubMed Web of Science ®Google Scholar
• SHAWYER L, PERRY MC: Tyrosine kinase inhibitors: from the emergence of targets to their clinical development. In: American Society of Clinical Oncology Educational Book. Shawyer L, Perry MC (Eds.), Lippincott, Williams and Wilkins, Baltimore, USA (200029–47.
   Google Scholar
• PRENDERGAST G, PERRY MC : Targeting farnesyltrans-ferase: is ras relevant? In: American Society of Clinica Oncology Educational Book. Prendergast G, Perry MC (Eds.), Lippincott, Williams and Wilkins, Baltimore, USA (2000):22–28.
   Google Scholar
• SCHIPPER H, GOH CR, WANG TL: Shifting the cancer paradigm: must we kill to cure? J Clin. Oncol (1995) 13 :801–807.
   Google Scholar
• REIFENSTEIN ECJ: Hydroxyprogesterone caproatetherapy in advanced endometrial cancer. Cancer (1971) 27:485–502.
   PubMed Web of Science ®Google Scholar
• KELLEY RM, BAKER WH: Progestational agents in thetreatment of carcinoma of the endometrium. N Engl. J. Med. (1971) 264:216.
   Google Scholar
• BONTE J: Medroxyprogesterone in the management ofprimary and recurrent or metastatic uterine adenocar-cinoma. Acta Obstet. Gynecol. Scand. (1972) (Suppl. 19):21.
   Google Scholar
• KOHORN El: Gestagens and endometrial carcinoma.Gynecol. Oncol. (1975) 4:398.
   Google Scholar
• QUINN MA, CAUCHI M, FORTUNE D: Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol. (1985) 21:314.
   PubMed Web of Science ®Google Scholar
• THIGPEN JT, BLESSING JA, DISAIA P: Oral medroxypro-gesterone acetate in advanced or recurrent endome-trial carcinoma: results of therapy and correlation with estrogen and progesterone levels. In: Endocri-nology of Malignancy (The Gynecologic Oncology Group experience). Baulieu EE, Slacobelli S, McGuire WL (Eds.), Parthenon, Park Ridge, NJ, USA (1980446–454.
   Google Scholar
• LENTZ S, BRADY M, SOPER JT, MAJOR F, REID G: High dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proc. ASCO (1994) 13:260.
   Google Scholar
• BONTE J: Hormonotherapie adjuvante par medroxy-progesterone dans le traitement de l'adenocarcinome endometrial au stage I. Med. et Hyg. (1977) 35:4193–4197.
   Google Scholar
• MALKASIAN GD, DECKER DG: Adjuvant progesteron therapy for stage I endometrial carcinoma. Int. J Gynecol. Obstet. (1978) 16:48–49.
   PubMedGoogle Scholar
• DEPALO G, MERSOM M, DEL VECCHIO M: A controlled clinical study of adjuvant medroxyprogesterone acetate (MPA) therapy in pathological stage I endome-trial cancer with myometrial invasion. Proc. ASCO (1985) 4:121.
   Google Scholar
• LEWIS G, SLACK N, MORTEL R: Adjuvant progesterone therapy in the primary definitive treatment of endometrial cancer. Gynecol Oncol. (1974) 2:368–376.
   PubMedGoogle Scholar
• MACDONALD RR, THORGOOD J, MASON MK: Ar andom-ized trial of progestogens in the primary treatment of endometrial carcinoma. Br. J Obstet. Gynecol (1988) 95:166–174.
   PubMedGoogle Scholar
• VERGOTE I, KJORSTAD K, ABELER V: A randomized trialof adjuvant progestogen in early endometrial cancer. Cancer (1989) 64:1011–1016.
   PubMed Web of Science ®Google Scholar
• CARBONE PP, CARTER SK: Endometrial cancer:Approach to development of effective chemotherapy. Gynecol. Oncol. (1974) 2:348–353.
   PubMedGoogle Scholar
• DEVITA VT, WASSERMAN TH, YOUNG RC, CARTER SK:Perspectives on research in gynecologic oncology: Treatment protocols. Cancer (1976) 38:509–525.
   PubMed Web of Science ®Google Scholar
• SUTTON GP, BLESSING JA, HOMESLEY HD, MCGUIRE W,ADCOCK L: A Phase II trial of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Cancer (1994) 73 (5):1453–1455.
   Google Scholar
• BARTON C, BUXTON EJ, BLACKLEDGE G: A Phase IIstudy of ifosfamide in endometrial cancer. Cancer Chemother. Pharmacol. (1990) 26:S4–6.
   PubMed Web of Science ®Google Scholar
• DEPPE G, COHEN CJ, BRUCKNER FIVV: Treatment ofadvanced en dometrial aden o carcin om a with cis-dichlorodiammine platinum (II) after intensive prior therapy. Gynecol Oncol. (1980) 10:51–54.
   PubMedGoogle Scholar
• SESKI J, EDWARDS CL, HERSON J: Cisplatinchemotherapy for disseminated endometrial cancer. Obstet. Gynecol (1982) 59:225–228.
   PubMed Web of Science ®Google Scholar
• THIGPEN JT, BLESSING JA, LAGASSE LD: Phase II trial ofcisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am. J. Clin. Oncol. (1984) 7:253–256.
   PubMed Web of Science ®Google Scholar
• THIGPEN JT, BLESSING JA, HOMESLEY HD: Phase II trialof cisplatin as first-line chemotherapy in patients with advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. (1989) 33:68–70.
   PubMed Web of Science ®Google Scholar
• TROPE C, GRUNDSELL H, JOHNSSON JE: A Phase II studyof cisplatinum for recurrent corpus cancer. Eur. Cancer (1980) 16:1025–1026.
   PubMedGoogle Scholar
• LONG HJ, PFEIFLE DM, WIEAND HS: Phase II evaluationof carboplatin in advanced endometrial carcinoma. J Natl. Cancer Inst. (1988) 80:276–278.
   PubMed Web of Science ®Google Scholar
• GREEN JB, GREEN S, ALBERTS DS: Carboplatin therapyin advanced endometrial cancer. Obstet. Gynecol. (1990) 75:696–700.
   PubMed Web of Science ®Google Scholar
• BURKE TVV, MUNKARAH A, KAVANAGH JJ: Treatment ofadvanced or recurrent endometrial carcinoma with single agent carboplatin. Gynecol Oncol (1993) 51:397–400.
   PubMed Web of Science ®Google Scholar
• SESKI J, EDWARDS CL, COPELAND L: Hex amethylmela-mine chemotherapy for disseminated endometrial cancer. Obstet. Gynecol. (1981) 58:361–363.
   PubMed Web of Science ®Google Scholar
• THIGPEN JT, BLESSING JA, BALL HG: Hex amethylmela-mine as first-line therapy in the treatment of advanced or recurrent carcinoma of the endometrium: A Phase II trial of the Gynecologic Oncology Group. Gynecol. Oncol. (1988) 31:435–438.
   PubMed Web of Science ®Google Scholar
• THIGPEN JT, BUCHSBAUM HJ, MANGAN CE: Phase II trialof adriamycin in the treatment if advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat. Rep. (1979) 63 :21–27.
   PubMedGoogle Scholar
• CALERO F, ASINS-CODONER E, JIMENO J: Epirubicin inadvanced endometrial adenocarcinoma: A Phase II study of the Grupo Ginecologico Espanol para el Tratamiento Oncologico (GGEM). Eur. J Cancer (1991) 27:864–866.
   PubMed Web of Science ®Google Scholar
• HAKES TB, RAYMOND V: Phase II study of idarubicin inadvanced endometrial carcinoma. Cancer Treat. Rep. (1987) 71:535–536.
   PubMedGoogle Scholar
• GREEN JB, GREEN S, O'TOOLE RV: Esorubicin inadvanced endometrial cancer: An ineffective and potentially toxic therapy. A Southwest Oncology Group study. Invest. New Drugs (1991) 9:191–193.
   PubMed Web of Science ®Google Scholar
• CHAUVERGNE J, FUMOLEAU P, CAPPELAERE P: Phase IIstudy of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC). Eur. Cancer (1993) 29A:350.
   PubMed Web of Science ®Google Scholar
• HILGERS RD, VON HOFF DD, STEPHENS RL: Mitoxan-trone in adenocarcinoma of the endometrium: A Southwest Oncology Group study. Cancer Treat. Rep. (1985) 69:1329–1330.
   PubMedGoogle Scholar
• MUSS HB, BUNDY BN, DISAIA P: Mitoxantrone forcarcinoma of the endometrium: A Phase II trial of the Gynecologic Oncology Group. Cancer Treat. Rep. (1987) 71:217–218.
   PubMedGoogle Scholar
• BOADLE DJ, TATERSALL MHN: Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma. Aust. NZ J. Obstet. Gynaecol. (1987) 27:341–342.
   PubMed Web of Science ®Google Scholar
• MUGGIA FM, BLESSING JA, SOROSKY JI, REID G: Phase II study of the pegylated lip osomal doxorubicin (Doxil7 in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group Study. Proc. ASCO (2000) 384(a).
   Google Scholar
• MUSS HB, BLESSING JA, HATCH K: Methotrexate in advanced enodmetrial carcinoma. A Phase II trial of the Gynecologic Oncology Group. Am. J. Clin. Oncol (1990) (13):61–63.
   Google Scholar
• DVORAK 0: Cytembena treatment of advanced gyneco-logic carcinomas. Neoplasma (1971) 18:461–464.
   PubMed Web of Science ®Google Scholar
• POPLIN EA, LIU PY, DELMORE JE et al: Phase II trial of oral Etoposide in recurrent or refractory endometrial adenocarcinoma: a Southwest Oncology Group study. Gynecol. Oncol. (1999) 74:432–435.
   PubMed Web of Science ®Google Scholar
• SLAYTON RE, BLESSING JA, DELGADO G: Phase II trial of etposide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Cancer Treat. Rep. (1982) 66:1669–1671.
   PubMedGoogle Scholar
• BROUN GOJ, BLESSING JA: A Phase II trial of vincristine given as a weekly intravenous bolus in advanced or recurrent endometrial carcinoma: A Phase II trial of the Gynecologic Oncology Group. Gynecol Oncol. (1993) 16:18–21.
   Google Scholar
• JACKSON DVJ, JOBSON VW, HOMESLEY HD: Vincristine infusion in refractory gynecologic malignancies. Gynecol. Oncol. (1986) 25:212–216.
   PubMed Web of Science ®Google Scholar
• KAVANAGH JJ, SAUL PB, WHARTON JT: A trial of continuous-infusion vinblastine in refractory endometrial adenocarcinoma. Gynecol. Oncol. (1987) 2 6 :236–239.
   Google Scholar
• THIGPEN JT, KRONMAL R, VOGEL S: A Phase II trial of vinblastine in patients with advanced or recurrent endometrial carcinoma. A Southwestern Oncology Group study. Am. J. Clin. Oncol. (1987) 10:429–431.
   PubMed Web of Science ®Google Scholar
• MUSS HB, BUNDY BN, ADCOCK L: Teniposide (VM-26) in patients with advanced endometrial cancer: APhase II trial of the Gynecologic Oncology Group. Am. J Clin. Oncol. (1991) 14:36–37.
   PubMed Web of Science ®Google Scholar
• MOORE DH, BLESSING JA, DUNTON C, BULLER RE, REID GC: Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. (1999) 75 (3):473–475.
   PubMed Web of Science ®Google Scholar
• ASBURY RF, BLESSING JA, MCGUIRE WP: Arninothiadia-zole (NSC 4728) in patients with advanced carcinoma of the endometrium. A Phase II study of the Gyneco-logic Oncology Group. Am. J. Clin. Oncol. (1990) 13:39–41.
   PubMed Web of Science ®Google Scholar
• ASBURY RF, BLESSING JA, REID GC, MCGUIRE WP: A Phase II trial of amonafide in patients with endome-trial cancer. A Gynecologic Oncology Group Study. Am. J. Clin. Oncol (1998) 21 (4):406–407.
   PubMed Web of Science ®Google Scholar
• BRENNER DE, GARBINO C, KASDORF H: A Phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies. Am. J. Clin. Oncol. (1982) 5:291–295.
   PubMed Web of Science ®Google Scholar
• HILGERS RD, LEGHA SS, JOHNSTON GAJ: m-AMSA and adenocarcinoma of the endometrium. A Southwest Oncology Group study. Invest. New Drugs (1984) 2:335–338.
   PubMed Web of Science ®Google Scholar
• STEHMAN FB, BLESSING JA, DELGADO G: Phase II evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: a Gyneco-logic Oncology Group study. Gynecol Oncol. (1983) 67:737–738.
   Google Scholar
• SLAYTON RE, BLESSING JA, DISAIA P: A Phase II clinical trial of diaziquone in the treatment of patients with recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am. J. Clin. Oncol. (1988) 11:612–613.
   PubMed Web of Science ®Google Scholar
• MUSS HB, BLESSING JA, DUBESHTER B: Ecninomycin in recurrent or metastatic encomtrial carcinoma: a Phase II trial of the Gynecologic Oncology Group. Am. J Clin. Oncol. (1991).
   Google Scholar
• VON HOFF DD, GREEN S, ALBERTS DS: Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. Am. J. Clin. Oncol. (1991) 14:193–194.
   PubMed Web of Science ®Google Scholar
• SLAYTON RE, FARAGGI D: A Phase II clinical trial of methyl-glyoxal-bisguanylhydrazone (MGBG) in advanced endometrial cancer. Proc. ASCO (1986) 5:119.
   Google Scholar
• THIGPEN JT, BLESSING JA, DISAIA P: A randomized comparison of adriamycin with or without cyclophos-phamide in the treatment of advanced or recurrent endometrial cancer. Proc. ASCO (1985) 4:115.
   Google Scholar
• MUGGIA FM, CHIA G, REED LJ: Doxorubicin-cyclophosphamide: effective chemotherapy for advanced endometrial adenocarcinoma. Am. J. Obstet. Gynecol (1977) 128:314–319.
   PubMed Web of Science ®Google Scholar
• CAMPORA E, VIDALI A, MAMMOLITI S: Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophospha-mide. Eur.J. Gynaec. Oncol. (1990) 11:181–183.
   PubMedGoogle Scholar
• BALL HG, BLESSING JA, LENTZ SS, MUTCH DG: APhase II trial of taxol in advanced and recurrent adenocarcinoma of the endometrium. Gynecol. Oncol (1996) 62:278–281.
   PubMed Web of Science ®Google Scholar
• THIGPEN JT, VANCE RB, KHANSUR T: The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin. Oncol (1995) 22 (Suppl. 12):67–75.
   Google Scholar
• LISSONI A, ZANETTA G, LOSA G, GABRIELE A, PARMA G, MANGIONI C: Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann. Oncol. (1996) 7:861–863.
   PubMed Web of Science ®Google Scholar
• THIGPEN JT, BLESSING JA, DI SAIA PJ, YORDAN E, CARSON LF, EVERS C: A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J. Clin. Oncol. (1994) 12:1408–1414.
   PubMed Web of Science ®Google Scholar
• THIGPEN JT, BLESSING JA, HOMESLEY HD: Phase III trial of doxorubicin +/- cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Proc. ASCO (1993) 12:261.
   Google Scholar
• •Large randomised controlled trial that set standards for current endometrial cancer care.
   Google Scholar
• AAPRO M, BOLIS G, CHEVALLIER B, MELVANDENBURG A, POVEDA A, POWINSKI A: An EORTC GCCG r an do mized Phase II trial of doxorubicin vs. doxorubicin +DDP in endometrial carcinoma. Proc. ASCO (1994) 13:275.
   Google Scholar
• FLEMING GF, BRUNETTO V, RADER BJ, CLARKE-PEARSON D, SOROSKY J, EATON L: Randomized trial of doxorubicin plus cisplatin versus DOX plus paclitaxel plus granulocyte colony-stimulating factor in patients with advanced or recurrent endometrial cancer A report on GOG protocol #163. Proc. ASCO (2000) 19:379a.
   Google Scholar
• SESKI J, EDWARDS CL, GERSHENSON D: Doxorubicin and cyclophosphamide chemotherapy for dissemi-nated endometrial cancer. Obstet. Gynecol. (1981) 58:88–91.
   PubMed Web of Science ®Google Scholar
• SELTZER V, VOGL SE, KAPLAN BH: Adriamycin and cisdiamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma. Gynecol. Oncol. (1984) 19:308–313.
   PubMed Web of Science ®Google Scholar
• PASMANTIER MW, COLEMAN M, SILVER RT: Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: Effects on both untreated and previously treated patients. Cancer Treat. Rep. (1985) 69:539–542.
   PubMedGoogle Scholar
• BARRETT RJ, BLESSING JA, HOMESLEY HD: Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. Am. J. Clin. Oncol. (1991).
   Google Scholar
• TROPE C, JOHNSSON JE, SIMONSEN E: Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. Am. J Obstet. Gynecol. (1984) 149:279–281.
   Google Scholar
• LOVECCHIO JL, AVERETTE HE, LICHTINGER M, TOWNSEND PA, GIRTANNER RW, FENTON AN: Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubi-cin, cisplatinum and megestrol acetate. Obstet. Gynecol. (1984) 63 :557–560.
   PubMed Web of Science ®Google Scholar
• TURBOW MM, BALLON SC, SIKIC BI: Cisplatin, doxorubicin and cyclophosphamide chemotherapy for advanced endometrial carcinoma. Cancer Treat. Rep. (1985) 69:465–467.
   PubMedGoogle Scholar
• HOFFMAN MS, ROBERTS WS, CAVANAGH D, PRAPHAT H, SOLOMON P, LYMAN GH: Treatment of recurrent and metastatic en dometrial cancer with cisplatin, dox orubicin, cyclophosphamide and megestrol acetate. Gynecol. Oncol. (1989) 35:75.
   PubMed Web of Science ®Google Scholar
• DUNTON CJ, PFEIFER SM, BRAITMAN LE: Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin and cyclophosphamide. Gynecol Oncol. (1991) 41:113–116.
   PubMed Web of Science ®Google Scholar
• HANCOCK KC, FREEDMAN RS, EDWARDS CL: Use of cisplatin, doxorubicin and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium. Cancer Treat. Rep. (1986) 70:789–791.
   PubMedGoogle Scholar
• DE OLIVEIRA CF, VAN DER BURG ME, OSORIO ME: Chemotherapy of advanced endometrial carcinoma with cyclophosphamide, adriamycin and cisplatin (CAP). First Meeting of the International Gynecologic Cancer Society (1987):Abstract 40.
   Google Scholar
• BURKE TW, STRINGER CA, MORRIS M: Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin and cyclophos-phamide. Gynecol Oncol. (1991) 40:264–267.
   PubMed Web of Science ®Google Scholar
• BURKE TVV, GERSHENSON D, MORRIS M et al.: Postopera-tive Adjuvant Cisplatin, Doxorubicin and Cyclophos-phamide (PAC) chemotherapy in women with high-risk en dometrial carcinoma. Gynecol. Oncol. (1994) 55:47–50.
   PubMed Web of Science ®Google Scholar
• GADDUCCI A, ROMANINI A, COSIO S et al.: Combination of cisplatin, epirubicin and cyclophosphamide (PEC Regimen) in advanced or recurrent endometrial cancer. A retrospective clinical study. Anticancer Res. (1999) 19:2253–2256.
   PubMed Web of Science ®Google Scholar
• ALBERTS DS, MASON NL, O'TOOLE RV: Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: a Southwest Oncology Group study. Gynecol. Oncol. (1987) 2 6:193–200.
   Google Scholar
• PIERGA JY, DIERAS V, ARAISO D et al: Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin and 5 fluorou-racil: a Phase II study. Gynecol. Oncol. (1996) 60:59–63.
   PubMed Web of Science ®Google Scholar
• PIERGA JY, DIERAS V, BEUZEBOC P et al.:Phase II trial of doxorubicin, 5 -fluorouracile, etoposide and cisplatin in advanced or recurrent endometrial carcinoma. Gynecol Oncol. (1997) 66:246–249.
   PubMed Web of Science ®Google Scholar
• FLEMING GF, FOWLER JM, WAGGONER SE: Phase I trial of escalating doses of paclitax el (TAX) combined with fixed doses of cisplatin (CIS) and doxorubicin (DOX) in patients with advanced gynecologic malignancies: a Gynecologic Oncology Group (GOG) trial. Proc. ASCO (1998) 17:361a.
   Google Scholar
• LISSONI A, GABRIELE A, GORGA G: Cisplatin-, epirubi-cin- and paclitax el-containing chemotherapy in uterine adenocarcinoma. Ann. Oncol. (1997) 8:969–972.
   PubMed Web of Science ®Google Scholar
• NISHIDA T, NAGASUE N, KISHI N: Apr elim in ary study of a combination chemotherapy with ifosfamide, adriamycin and cisplatin for endometrial carcinoma. Acta Obst. Gynaec. fpn. (1988) 40:1883–1888.
   Google Scholar
• PRICE FV, EDWARDS RP, KELLEY JL, KUNSCHNER AJ, HART LA: A trial of outpatient paclitaxel and carboplatin for advanced, recurrent and histologic high-risk endometrial carcinoma: preliminary report. Semin. Oncol (1997) 24 (Suppl. 15):S15–78–82.
   Google Scholar
• SORBE B, WOLMESJO E, FRANKENDAL B: VM-26-vincristine-cisplatin combination chemotherapy in the treatment of primary advanced and recurrent endometrial carcinoma. Obstet. Gynecol. (1989) 73:343–348.
   PubMed Web of Science ®Google Scholar
• HALL JB, HIGGINS RV, NAUMANN RW, GROBLEWSKI M: Phase II Study of top otecan and ciplatinum Stage 3 and 4 or for recurrent endometrial cancer. Proc. ASCO (2000):Abstract 1622.
   Google Scholar
• SANTORO A, MAIORINO L, SANTORO M: Carboplatin and vinorelbine combination for treatment of advanced endometrial carcinoma. Proc. ASCO (1998) 17:375a.
   Google Scholar
• LONG HJ, LANGDON RM, WIEAND HS: Phase II trial of methotrex ate, vinblastine, doxorubicin and cisplatin (MVAC) in women with advanced endometrial carcinoma. Proc. ASCO (1991) 10:184.
   Google Scholar
• STRINGER CA, GERSHENSON DM, BURKE TVV, EDWARDS CL, GORDON AN: Adjuvant chemotherapy with cisplatin, doxorubicin and cyclophosphamide (PAC) for early stage high risk endometrial cancer: a prelimi-nary analysis. Gynecol Oncol. (1990) 38(3):305–308.
   PubMed Web of Science ®Google Scholar
• CHAN KL, DOTTINO P, BEDDOE A, COHEN CJ: Adjuvant doxorubicin, cisplatin and etoposide (APE) chemotherapy in high risk endometrial carcinoma. Proc. ASCO (1998) 17:363a.
   Google Scholar
• JENNINGS S, DOTTINO P, JOHNSTON C: Adjuvant cisplatin, doxorubicin and etoposide and pelvic radiotherapy for advanced stage or virulent histologic subtypes of endometrial cancer. Proc. ASCO (1993) 12:268.
   Google Scholar
• SMITH MR, PETERS WA, DRESCHER CW: Cisplatin, doxorubicin hydrochloride and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am. J. Obstet. Gynecol. (1994) 170:1677–1682.
   PubMed Web of Science ®Google Scholar
• PIVER MS, LELE SB, PATSNER B: Melphalan, 5 -flur ouracil and medroxyprogesterone acetate in metastatic endometrial carcinoma. Obstet. Gynecol. (1986) 67:261–264.
   PubMed Web of Science ®Google Scholar
• COHEN CJ, DEPPE G, BRUCKNER HW: Treatment of advanced adenocarcinoma of the endometruim with melphalan, 5-fluorouracil and medroxyprogesterone acetate: a preliminary study. Obstet. Gynecol (1977) 50:415–417.
   PubMed Web of Science ®Google Scholar
• DEPPE G, JACOBS AJ, BRUCKNER HW: Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil and megesterol acetate. Am. J. Obstet. Gynecol. (1981) 140:313–316.
   PubMed Web of Science ®Google Scholar
• BRUCKNER H, DEPPE G: Combination chemotherapy of advanced endometrial aden o carcin om a with adriamycin, cyclophosphamide, 5 -fluouracil and medroxyprogesterone acetate. Obstet. Gynecol. (1977) 50 (Suppl.):10–12.
   Google Scholar
• FUNG MF, KREPART GV, LOTOCKI RJ, HEYWOOD M: Treatment of recurrent and metastatic adenocarci-noma of the endometrium with cisplatin, doxorubi-cin, cyclophosphamide and medroxyprogesterone acetate. Obstet. Gynecol. (1991) 78:1033.
   PubMed Web of Science ®Google Scholar
• BAFALOUKOS D, ARAVANTINOS G, SAMONIS G, KATSIFIS G, BAKOYIANNIS C, KOSMIDIS P: Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: a Hellenic cooperative oncology group study. Oncology (1999) 56(3):198–201.
   PubMed Web of Science ®Google Scholar
• PIVER MS, FANNING J, BAKER TR: Phase II trial of cisplatin, adriamycin and etoposide for metastatic endometrial adenocarcinoma. Am. J. Gin. Oncol (1991) 14:200–202.
   PubMed Web of Science ®Google Scholar
• DECOSTER JM, BONTE J, MARCQ A: Medroxyproges-terone acetate release from silastic devices as replace-ment for local irradiation by radium tubes in preoperative intrauterine packing for endometrial adenocarcinoma. Gynecol. Oncol. (1977) 5:189–195.
   PubMed Web of Science ®Google Scholar
• BOKHMAN JV, CHEPICK OF, VOLKOVA AT: Adjuvant hormone therapy of primary endometrial adenocarci-noma with oxyprogesterone caproate. Gynecol. Oncol. (1981) 11:371–378.
   PubMed Web of Science ®Google Scholar
• BOKHMAN JV, CHEPICK OF, VOLKOVA AT: Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? Gynecol. Oncol. (1985) 20:139–155.
   Google Scholar
• GAL D: Hormonal therapy for lesions of the endometrium. Semin. Oncol. (1986) 13 (Suppl. 4) :33–36.
   Google Scholar
• MARKMAN M, KENNEDY A, WEBSTER K: lzuprolide in the treatment of endometrial cancer. Gynecol. Oncol (1997) 66:542.
   PubMed Web of Science ®Google Scholar
• ALDERS J, ABELER V, KOLSTAD P, ONSRUD M: Postopera-tive external irradiation and prognostic parameters in Stage I endometrial carcinoma. Obstet. Gynecol. (1980) 56:419.
   PubMed Web of Science ®Google Scholar
• FIGO stages: 1988 revision. Gynecol. Oncol. (1989) 35:125–127.
   Google Scholar
• CREUTZBERG CL, VAN PUTTEN WLJ, KOPER PCM: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet (2000) 255:1404–1411.
   Google Scholar
• •New philosophy in care of women with stage 1 intermediate risk uterine cancer.
   Google Scholar
• BERGMAN 1, BEELEN ML, GALLEE MP, HOLLEMA H, BENRAADT J, VAN LEUWEN FE: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centre's ALERTGroup . Assess-ment of liver and endometrial cancer risk following tamoxifen. Lancet (2000) 356:881–887.
   Google Scholar